Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 10/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7093747 | 0.85 | MAOA (0.61) | NPC1POLBESR2MAOAALDH1A1 | |
| SCHEMBL6995943 | 0.81 | GLA (0.61) | NPC1POLBALDH1A1HPGDTDP1 | |
| SCHEMBL10405182 | 0.80 | MAOA (0.44) | MAOAALDH1A1MAOBKDM4EKMT2A | |
| SCHEMBL7001341 | 0.78 | RAB9A (0.63) | NPC1ALDH1A1HPGDMAOBKDM4E | |
| SCHEMBL6995631 | 0.76 | HSD17B3 (0.60) | MAOAHSD17B3ALDH1A1TDP1ERAP1 | |
| SCHEMBL220708 | 0.75 | HSD17B3 (0.65) | MIFNPC1POLBESR2MAOA | |
| SCHEMBL30405545 | 0.75 | HSD17B3 (0.65) | MIFNPC1POLBESR2MAOA | |
| SCHEMBL29066603 | 0.75 | ESR2 (0.61) | MIFNPC1POLBESR2PTGS1 | |
| SCHEMBL28920340 | 0.75 | POLB (0.69) | MIFNPC1POLBESR2HSD17B3 | |
| SCHEMBL6037595 | 0.74 | POLB (0.59) | MIFNPC1POLBESR2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032265-B1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORP (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030082510-A1 | Psoralens for pathogen inactivation | CERUS CORPORATION (US) | 2003-05-01 | — | — | US | disclosed |
| US-6455286-B1 | MIXING PSORALEN COMPOUND OF DEFINED STRUCTURE WITH BIOLOGICAL COMPOSITION SUCH AS BLOOD OR PLATELETS, THEN PHOTOACTIVATING COMPOUND TO DEACTIVATE PATHOGEN | CERUS CORPORATION | 2002-09-24 | — | — | US | disclosed |
| EP-1032265-A4 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORP (US) | 2001-05-30 | — | — | EP | disclosed |
| US-6133460-A | HAVE PRIMARY AMINO SUBSTITUTIONS ON THE 3-, 4-, 5-, AND 8-POSITIONS OF THE PSORALEN WHICH PERMIT BINDING TO NUCLEIC ACID OF PATHOGENS; CONDITIONS THAT PHOTOACTIVATE THESE PSORALENS RESULT IN INACTIVATION OF PATHOGENS WHICH CONTAIN NUCLEIC ACID | CERUS CORPORATION (US) | 2000-10-17 | — | — | US | disclosed |
| EP-1032265-A1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | Cerus Corporation (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999026476-A1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORPORATION (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082510-A1 | Psoralens for pathogen inactivation | BPGM, XPA, RAD50 | MIF 2561/4885NPC1 4191/4885POLB 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.